Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

Many people find that they regain weight after dieting. Now, a new study points to something that may make it easier to ...

Patients who switched from weekly to monthly injections of VK2735 retained most of their weight loss, with side effects similar to placebo ...

Viking Therapeutics Inc. VKTX stock surged on Tuesday after the company released positive topline results from its much-anticipated VK2735 maintenance trial. The dual GLP-1 and GIP receptor agonist ...

Recent research suggests that “microdosing” GLP-1 medications may still lead to weight loss. However, lower doses were ...

The basic principle of weight loss is straightforward: if you consume fewer calories than you burn, you'll lose weight. In practice though, this isn't usually so easy or simple. Alongside counting ...

O'Neal reveals how Zepbound helped improve his sleep, energy and weight. Basketball Network I Have A ‘Fat’ Disease That Doesn’t Respond To Diet Or Exercise. I Hate That I Still Feel Ashamed. “I am no ...

GLP-1s, including Ozempic, Mounjaro and Wegovy, have become increasingly popular for treating obesity and Type 2 diabetes. In addition to helping with weight loss by reducing appetite, they may also ...

Maintaining a stable weight loss is the biggest struggle for obese individuals, yet new research from University of Copenhagen have allowed researchers new insights into the complex processes involved ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults undergoing duodenal mucosal resurfacing ...

The weight-loss drug market is booming, with biotech firms racing to capture a slice of the fast-growing sector dominated by Novo Nordisk and Eli Lilly.